CAP2 Activators
CAP2 activators encompass a range of chemical compounds that enhance the functional activity of CAP2, a protein directly involvedin the regulation of actin cytoskeleton dynamics and cellular motility. Forskolin, a direct stimulator of adenylyl cyclase, leads to increased cAMP levels, which activates protein kinase A (PKA). PKA can phosphorylate CAP2, thereby promoting actin filament assembly, which is critical to CAP2's role in maintaining cell structure and motility. Similar in function, Epinephrine and Dibutyryl-cAMP elevate cAMP levels, with the former binding to adrenergic receptors and the latter being a cell-permeable analog of cAMP. These lead to PKA activation and subsequent phosphorylation of CAP2, enhancing its regulatory role in actin dynamics. Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which could phosphorylate CAP2, affecting cytoskeletal rearrangement.
Additionally, several compounds act indirectly to sustain or enhance CAP2 activity through inhibition of dephosphorylation or stabilization of the actin structure. Calyculin A and Okadaic Acid, both inhibitors of protein phosphatases PP1 and PP2A, prevent dephosphorylation, leading to enhanced phosphorylation states and activity of CAP2. Lithium Chloride inhibits GSK-3, potentially stabilizing CAP2 and promoting its influence on actin filament organization. Rolipram increases cAMP levels by inhibiting PDE4, which indirectly leads to the activation of CAP2 via PKA signaling pathways. On the other hand, Vinblastine, Jasplakinolide, and Cytochalasin D influence actin filament dynamics, with the former disrupting microtubule formation and the latter two affecting actin stability and polymerization. Such disturbances necessitate the compensatory activity of CAP2 to maintain cellular integrity. Lastly, Y-27632, a ROCK inhibitor, leads to changes in actin stress fibers and focal adhesions, processes that CAP2 is known to modulate, potentially increasing the functional activity of CAP2 in response to altered cytoskeletal dynamics. These CAP2 activators, through their varied effects on cellular signaling and cytoskeletal components, underscore the intricate regulatory mechanisms controlling CAP2 activity and its pivotal role in cytoskeletal organization.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Directly stimulates adenylyl cyclase, leading to an increase in cAMP levels within the cell. Elevated cAMP enhances protein kinase A (PKA) activity, which can phosphorylate transcription factors to upregulate BTNL2 expression and activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase-4 (PDE4) inhibitor, increases intracellular cAMP by preventing its degradation, thereby enhancing PKA activity which, in turn, can enhance BTNL2 function through increased transcription factor phosphorylation and upregulation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Binds to EP2/EP4 receptors and activates adenylate cyclase, increasing cAMP levels. This cascade can result in enhanced BTNL2 activity through the same mechanism as Forskolin by PKA-mediated signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-specific inhibitor of phosphodiesterases, elevates cAMP by preventing its degradation, leading to activation of PKA and potential upregulation of BTNL2 expression and function. | ||||||
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
Precursor for nitric oxide synthesis, which can activate guanylate cyclase and increase cGMP levels. While typically associated with smooth muscle relaxation, cGMP can also influence transcriptional regulation, potentially enhancing BTNL2 activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Activates adrenergic receptors, particularly β-adrenergic receptors which stimulate adenylyl cyclase, resulting in increased cAMP and activation of PKA, potentially leading to enhanced BTNL2 activity. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Through its action on H2 receptors, histamine can increase cAMP production, thereby activating PKA and potentially influencing the expression and function of BTNL2. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Activates dopamine receptors, specifically D1-like receptors which are coupled to adenylyl cyclase, promoting cAMP synthesis, PKA activation, and subsequent potential upregulation of BTNL2. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Another PDE5 inhibitor that increases cGMP levels, potentially leading to enhanced BTNL2 expression and activity through similar mechanisms as Sildenafil. | ||||||
Amrinone | 60719-84-8 | sc-207288 | 1 g | $193.00 | ||
Inhibits PDE3, leading to increased cAMP levels which can augment PKA activity and might lead to increased BTNL2 function due to amplified transcription factor activation. | ||||||